Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
- Previous Close
29.10 - Open
29.15 - Bid --
- Ask --
- Day's Range
29.10 - 29.80 - 52 Week Range
23.50 - 53.70 - Volume
100,539 - Avg. Volume
107,404 - Market Cap (intraday)
2.292B - Beta (5Y Monthly) --
- PE Ratio (TTM)
53.73 - EPS (TTM)
0.55 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield 0.80 (2.71%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
--
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is based in New Taipei City, Taiwan.
www.ccsb.com.twRecent News: 1762.TW
View MorePerformance Overview: 1762.TW
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1762.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1762.TW
View MoreValuation Measures
Market Cap
2.29B
Enterprise Value
2.87B
Trailing P/E
53.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
2.20
Enterprise Value/EBITDA
12.17
Financial Highlights
Profitability and Income Statement
Profit Margin
1.54%
Return on Assets (ttm)
-0.28%
Return on Equity (ttm)
0.59%
Revenue (ttm)
1.29B
Net Income Avi to Common (ttm)
19.8M
Diluted EPS (ttm)
0.55
Balance Sheet and Cash Flow
Total Cash (mrq)
275.13M
Total Debt/Equity (mrq)
25.36%
Levered Free Cash Flow (ttm)
674.56M